In The Media

EyewireTV
October 19, 2022

CLINICAL TRIAL DOWNLOAD: Data From the Phase 2b Trial of OPT-302 October 1, 2022

EyeWorld Onsite 
September 30, 2022

Opthea CEO discusses updates on OPT-302 for treatment of wet AMD

September 30, 2022

August 16, 2022
December 19, 2019
August 8, 2019
Biotech Daily: Doctor Boreham’s Crucible

August 16, 2019

June 14, 2019
May 16, 2019
small cap companies
March 15, 2019
Major Inflection Points for Opthea in 2019 as
Case for Positive Results Build
March 11, 2019
Major Inflection Points for Opthea in 2019 as
Case for Positive Results Build
March 11, 2019
The Australian Financial Review
February 27, 2019
Top Six Stock Picks 2019
December 21, 2018
Opthea’s Strategy to Build Value for OPT-302
December 03, 2018
ASX, The CEO Sessions – Opthea Limited
February 16, 2016
Bell Potter – Top 3 Stocks in Healthcare & Biotech for 2016 – Opthea
January 08, 2016
Bioshares Report
February 13, 2015
The Australian, Special Edition The Deal – 30 Years of Executive Women. CEO: Selling science to Wall Street
December 03, 2015
Eureka Report – Opthea’s interview with Alan Kohler
December 02, 2015
Interview at Ophthalmology Innovation Summit, USA – Opthea taking new approach to combat wet AMD
November 12, 2015
Merger Market: Circadian Technologies
July 06, 2015
CommSec Executive Series: CEO Circadian Technologies Ltd
June 17, 2015
Channel 9 News Wet AMD & OPT-302 Feature Story
March 20, 2015
Biotech Daily CEO Interview
March 06, 2015
miVision Article: Australian Treatment for Wet AMD to be Trialled
March 01, 2015
OzEquities Newsletter
November 14, 2014
Bioshares Report 
November 14, 2014
Market Analysis Report – May 12 2014
May 12, 2014
Channel 9 News LAM feature story
April 02, 2012